{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:43:06Z","timestamp":1785300186605,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008079","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T00:00:00Z","timestamp":1352851200000}}],"reference-count":149,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008079.pub2","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T19:35:07Z","timestamp":1352403307000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia"],"prefix":"10.1002","volume":"2012","author":[{"given":"Kathrin","family":"Bauer","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Rancea","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Roloff","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit; Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Elter","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,14]]},"reference":[{"key":"10.1002\/14651858.CD008079.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0002|cit2","first-page":"280a","article-title":"Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: preliminary results from CALGB 9712","volume":"20 (Pt 1)","author":"Byrd","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008079.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD008079.pub2-BIB0004|cit4","first-page":"A","article-title":"Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (CLL) patients: results from CALGB 9712","volume":"98","author":"Byrd","year":"2001","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0006|cit6","first-page":"440a","article-title":"Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: Cancer and Leukemia Group B (CALGB) Study 9712","volume":"102","author":"Morrison","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD008079.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1182\/blood.V110.11.756.756","article-title":"Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: a comparative analysis of 3 Cancer and Leukemia Group B studies (CALGB 9011, 9712, 19901)","volume":"110","author":"Morrison","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/blood.V114.22.539.539","article-title":"Treatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB Study 9712","volume":"114","author":"Woyach","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood.V114.22.538.538","article-title":"Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL\/MW) and the \"Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du Sang\" (GOELAMS) : CLL2007FMP (for fit medically patients)","volume":"114","author":"Lepretre","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood.V118.21.1797.1797","article-title":"Interest of early determination of bone marrow MRD by a sensitive 6-color flow cytometry in the evaluation of response: the experience of the CLL2007FMP, an intergroup phase III randomized multicentric trial comparing fludarabine cyclophosphamide (FC) and rituximab (FCR) versus FC and MabCampath (FCCam) in previously untreated B-chronic lymphocytic leukemia patients","volume":"118","author":"Letestu","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood.V116.21.698.698","article-title":"CLL2007FMP, a phase III randomized multicentric trial of the French Cooperative Group on CLL and WM (FCGCLL\/MW) and the \"Groupe Ouest-Est D'etudes Des Leucemies Aigues Et Autres Maladies Du Sang\" (GOELAMS): immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) yields a significantly better response than fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated B-chronic lymphocytic leukemia patients as evaluated by a sensitive 6 color flow cytometry MRD","volume":"116","author":"Remi","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V112.11.326.326","article-title":"Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial","volume":"112","author":"Boettcher","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD008079.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/leu.2009.140","article-title":"Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis","volume":"23","author":"Bottcher","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/blood.V118.21.2863.2863","article-title":"Second-line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamid alone (FC) for chronic lymphocytic leukemia (CLL) within the CLL8-protocol of the German CLL Study Group (GCLLSG)","volume":"118","author":"Cramer","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.V116.21.50.50","article-title":"High-resolution SNP-array profiling of chronic lymphocytic leukemia","volume":"116","author":"Edelmann","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD008079.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1182\/blood.V114.22.3438.3438","article-title":"Health related quality of life (HRQOL) in patients receiving chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) or fludarabine and cyclophosphamide (FC) for first line therapy with advanced chronic lymphocytic leukemia (CLL)","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD008079.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood-2010-04-282228","article-title":"Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis","volume":"117","author":"Eichhorst","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.V118.21.977.977","article-title":"Prediction of poor outcome in CLL patients treated with FCR (fludarabine, cyclophosphamide, rituximab) in the CLL8 trial of the German CLL Study Group (GCLLSG)","volume":"118","author":"Fink","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood.V116.21.918.918","article-title":"Serum factors predict therapeutic outcome in patients with chronic lymphocytic leukemia treated in the CLL8 trial of the German CLL Study Group (GCLLSG)","volume":"116","author":"Fink","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0023|cit21","doi-asserted-by":"crossref","unstructured":"Hallek M Fingerle-Rowson G Phase III trial of combined immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) versus chemotherapy with fludarabine and cyclophosphamide (FC) alone in patients with previously untreated chronic lymphocytic leukaemia CLL-8 \/ ML17102 Protocol of the German CLL Study Group (GCLLSG). www.dcllsg.de\/en\/trial\/cll8\/index.php (only public data used). 2004 (accessed 17 August 2012)","DOI":"10.1186\/ISRCTN02757147"},{"issue":"22","key":"10.1002\/14651858.CD008079.pub2-BIB0021|cit22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood.V114.22.535.535","article-title":"First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an International Group of Investigators and the German CLL Study Group","volume":"114","author":"Hallek","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD008079.pub2-BIB0022|cit23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V112.11.325.325","article-title":"Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL)","volume":"112","author":"Hallek","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood.V112.11.781.781","article-title":"Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial","volume":"112","author":"Stilgenbauer","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood.V116.21.2427.2427","article-title":"Genetics of patients with F-refractory CLL or early relapse after FC or FCR: results from the CLL8 trial of the GCLLSG","volume":"116","author":"Zenz","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD008079.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood.V114.22.1267.1267","article-title":"TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial of the GCLLSG","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V106.11.5046.5046","article-title":"Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: results from a phase II study","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2141.2010.08317.x","article-title":"A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia","volume":"152","author":"Hillmen","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD008079.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood.V110.11.752.752","article-title":"NCRI CLL201 trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008079.pub2-BIB0031|cit31","first-page":"119","article-title":"NCRI CLL201 Trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL","volume":"141","author":"Hillmen","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"22","key":"10.1002\/14651858.CD008079.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood.V114.22.2338.2338","article-title":"FC-gamma receptor (FCGR) 2A and 3A polymorphisms do not influence the outcome of relapsed or refractory CLL patients treated with rituximab, fludarabine, and cyclophosphamide (R-FC) or fludarabine, and cyclophosphamide (FC) alone","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD008079.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood.V114.22.1742.1742","article-title":"Higher doses of rituximab may be required for patients with CLL as compared to NHL based on population pharmacokinetic (PK) modeling","volume":"114","author":"Li","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD008079.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.V114.22.1368.1368","article-title":"Quality-adjusted survival (Q-TWiST) analysis of patients with relapsed or refractory chronic lymphocytic leukaemia treated with rituximab plus fludarabine and cyclophosphamide (R-FC) versus FC alone","volume":"114","author":"Robak","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD008079.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"lba","DOI":"10.1182\/blood.V112.11.lba-1.lba-1","article-title":"Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial","volume":"112","author":"Robak","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD008079.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/blood.V114.22.4528.4528","article-title":"Long-term health outcomes and costs associated with the use of rituximab in combination with fludarabine and cyclophosphamide (R-FC) in the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) in Poland","volume":"114","author":"Robak","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Wierda W Jewell RC Kipps TJ D\u00fcrig J Griskevicius L Stilgenbauer S Correlations between ofatumumab exposure and treatment outcomes for patients with chronic lymphocytic leukemia (CLL) treated with frontline ofatumumab, fludarabine, and cyclophosphamide chemoimmunotherapy (Abstract 1793) Blood 2011","DOI":"10.1182\/blood.V118.21.1793.1793"},{"issue":"22","key":"10.1002\/14651858.CD008079.pub2-BIB0040|cit39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V114.22.207.207","article-title":"Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial","volume":"114","author":"Wierda","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1002\/14651858.CD008079.pub2-BIB0039|cit40","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.2008.18.8698","article-title":"Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?","volume":"27","author":"Ahmadi","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/10428190903499702","article-title":"New agents for the treatment of genetically high-risk chronic lymphocytic leukemia","volume":"51","author":"Bazargan","year":"2010","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0043|cit43","first-page":"74a","article-title":"Interim results from a phase I study of lumiliximab (IDEC-152, anti-CD23 antibody) therapy for relapsed refractory CLL","volume":"102","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0044|cit44","first-page":"73a","article-title":"The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients","volume":"102","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2003-05-1443","article-title":"Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia","volume":"102","author":"Castagna","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/13543780902832679","article-title":"Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders","volume":"18","author":"Castillo","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00277-008-0582-9","article-title":"A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL","volume":"88","author":"Decker","year":"2009","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0048|cit48","first-page":"25","article-title":"Pentostatin and rituximab in the treatment of patients with B-cell malignancies","volume":"14","author":"Drapkin","year":"2000","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.leukres.2009.07.008","article-title":"Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years","volume":"34","author":"Faderl","year":"2010","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0889-8588(18)30496-9","article-title":"Management of chronic lymphocytic leukemia","volume":"4","author":"Han","year":"1990","journal-title":"Hematology - Oncology Clinics of North America"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood.V114.22.3432.3432","article-title":"Comparative efficacy of first line therapies for chronic lymphocytic leukemia: a systematic review and meta-analyses","volume":"114","author":"Janssens","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0053|cit53","first-page":"2381","article-title":"Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia","volume":"114","author":"Keating","year":"2009","journal-title":"Drug Discovery"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0054|cit54","first-page":"101","article-title":"Ofatumumab","volume":"9","author":"Keating","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood.V116.21.699.699","article-title":"The safety and tolerability of oral fludarabine, {+\/-}oral cyclophosphamide and iv rituximab therapy in previously untreated patients with chronic lymphocytic leukaemia (CLL) aged >=65 years - interim analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 study","volume":"116","author":"Mulligan","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1182\/blood.V114.22.3757.3757","article-title":"Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab for treatment of indolent B-cell malignancies","volume":"114","author":"Negrea","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/blood-2008-09-178822","article-title":"Dasatinib induces a response in chronic lymphocytic leukemia","volume":"113","author":"Pitini","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/10428190802340192","article-title":"Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia","volume":"49","author":"Quinn","year":"2008","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V112.11.327.327","article-title":"Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia","volume":"112","author":"Reynolds","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood.V114.22.1662.1662","article-title":"Safety and efficacy of bendamustine with or without rituximab for the treatment of heavily pretreated CLL and lymphoma patients. A multicenter retrospective study","volume":"114","author":"Rigacci","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0061|cit61","first-page":"1","article-title":"Recent advances and future directions using monoclonal antibodies for B-cell malignancies","volume":"26","author":"Rosen","year":"1999","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/leu.2009.240","article-title":"R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia","volume":"24","author":"Tonino","year":"2010","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0064|cit64","unstructured":"Alemtuzumab and rituximab for consolidation in CLL (NCT00771602) Ongoing study August 2008"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0065|cit65","unstructured":"A study to compare subcutaneous versus intravenous MabThera (rituximab) in combination with chemotherapy in patients with CLL (NCT01292603) Ongoing study February 2011"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0066|cit66","unstructured":"Fludarabine, cyclophosphamide, and rituximab followed by rituximab or observation in treating older patients with previously untreated CLL (NCT00645606) Ongoing study November 2007"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0067|cit67","unstructured":"Intensified rituximab pre-phase before FluC-R in untreated CLL (NCT01370772) Ongoing study May 2011"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0068|cit68","unstructured":"Rituximab and alemtuzumab in treating older patients with progressive CLL (NCT01013961) Ongoing study October 2010"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0069|cit69","first-page":"226","article-title":"A phase II study of chlorambucil + rituximab (Clb-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results","volume":"96","author":"Foa","year":"2011","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V118.21.294.294","article-title":"Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment","volume":"118","author":"Foa","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V116.21.2462.2462","article-title":"A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis","volume":"116","author":"Foa","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1200\/jco.2011.29.15_suppl.6629","article-title":"A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the induction phase","volume":"29","author":"Mauro","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0073|cit73","unstructured":"A study comparing RO5072759 (GA101) 1000 mg versus 2000 mg in patients with previously untreated chronic lymphocytic leukaemia (NCT01414205) Ongoing study September 2011"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0074|cit74","unstructured":"A study of RO5072759 with chlorambucil in patients with previously untreated CLL (NCT01010061) Ongoing study November 2009"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0075|cit75","unstructured":"Rituximab, fludarabine, and cyclophosphamide or observation alone in treating patients with stage 0, I, or II CLL (NCT00275054) Ongoing study October 2005"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0076|cit76","unstructured":"Ofatumumab added to FC versus FC in relapsed subjects with CLL (NCT00824265) Ongoing study March 2009"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0077|cit77","unstructured":"Ofatumumab maintenance treatment versus no further treatment in relapsed CLL responding to induction therapy (PROLONG) (NCT01039376) Ongoing study May 2010"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0078|cit78","unstructured":"Ofatumumab versus physicians' choice in subjects with bulky fludarabine-refractory chronic lymphocytic leukaemia Ongoing study April 2011"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0079|cit79","unstructured":"Rituximab versus observation as maintenance therapy in CLL (NCT01118234) Ongoing study December 2009"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0080|cit80","unstructured":"A study of maintenance treatment with rituximab in patients with progressive CLL (NCT00718549) Ongoing study July 2009"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0081|cit81","unstructured":"Ofatumumab + chlorambucil versus chlorambucil monotherapy in previously untreated patients with CLL (NCT00748189) Ongoing study December 2008"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0082|cit82","first-page":"225","article-title":"Rituximab therapy of chronic lymphocytic leukemia patients in remission","volume":"96","author":"Zagoskina","year":"2011","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.V116.21.2464.2464","article-title":"Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: initial results of a phase II trial","volume":"116","author":"Badoux","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Bosch F Abrisqueta P Villamor N Terol M Ribera JM Gonzalez-Barca E Rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) is a highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia (Abstract 2097) Blood 2008","DOI":"10.1182\/blood.V112.11.2097.2097"},{"issue":"1","key":"10.1002\/14651858.CD008079.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD008079.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/10428190903150839","article-title":"Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901","volume":"50","author":"Byrd","year":"2009","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2009.133","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia","volume":"23","author":"Castro","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1182\/blood.V116.21.4638.4638","article-title":"Ofatumumab and high-dose methylprednisolone is an effective salvage treatment for heavily pretreated, unfit or refractory patients with chronic lymphocytic leukemia: single institution experience","volume":"116","author":"Castro","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0091|cit91","unstructured":"Cheung M Tey R Haynes A Rituximab in chronic lymphocytic leukemia. Program in Evidence-based Care. NGC:007886. 2009. ngc.gov\/content.aspx?id=16388&search=Chronic+lymphocytic+leukemia (accessed 17 August 2012)"},{"issue":"8","key":"10.1002\/14651858.CD008079.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008079.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood.V108.11.2840.2840","article-title":"Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III-trials of the German CLL Study Group","volume":"108","author":"Cramer","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3109\/10428191003717746","article-title":"The future of CD20 monoclonal antibody therapy in B-cell malignancies","volume":"51","author":"Czuczman","year":"2010","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0096|cit96","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"26","key":"10.1002\/14651858.CD008079.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008079.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-008-0566-9","article-title":"Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"88","author":"Elter","year":"2009","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood.V112.11.330.330","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG)","volume":"112","author":"Fischer","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V114.22.205.205","article-title":"Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG)","volume":"114","author":"Fischer","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD008079.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood.V116.21.1387.1387","article-title":"Chemoimmunotherapy with chlorambucil and the type II CD20-antibody GA101 in patients with chronic lymphocytic leukemia and comorbidity: results of the run-in phase of the CLL11 (BO21004) trial","volume":"116","author":"Goede","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/cncr.23271","article-title":"Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network","volume":"112","author":"Hainsworth","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD008079.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"9747","key":"10.1002\/14651858.CD008079.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0108|cit108","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0109|cit109","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0110|cit110","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"35","key":"10.1002\/14651858.CD008079.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood.V114.22.3428.3428","article-title":"An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-Cell chronic lymphocytic leukaemia (CLL)","volume":"114","author":"Hillmen","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD008079.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD008079.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2011.08597.x","article-title":"Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study","volume":"153","author":"Iannitto","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD008079.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/14712598.5.9.1225","article-title":"Monoclonal antibody therapy of leukaemias and lymphomas","volume":"5","author":"Jacobs","year":"2005","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.25028","article-title":"Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia","volume":"116","author":"Kay","year":"2010","journal-title":"Cancer"},{"issue":"18","key":"10.1002\/14651858.CD008079.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11912-007-0044-x","article-title":"Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia","volume":"9","author":"Lamanna","year":"2007","journal-title":"Current Oncology Reports"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood.V110.11.3115.3115","article-title":"Pentostatin, cyclophosphamide, rituximab, and mitoxantrone (PCRM): a new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR","volume":"110","author":"Lamanna","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1741-7015-9-36","article-title":"Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis","volume":"9","author":"Lanini","year":"2011","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0122|cit122","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-07-6663","article-title":"Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1182\/blood-2009-06-225474","article-title":"Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma","volume":"114","author":"Li","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD008079.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood.V114.22.884.884","article-title":"Phase I study of RO5072759 (GA101) in relapsed\/refractory chronic lymphocytic leukemia","volume":"114","author":"Morschhauser","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0127|cit127","unstructured":"National Institute for Health and Clinical Excellence Rituximab for the first-line treatment of chronic lymphocytic leukaemia. 2009. www.nice.org.uk\/nicemedia\/live\/11907\/44906\/44906.pdf (accessed 17 August 2012)"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0128|cit128","unstructured":"National Institute for Health and Clinical Excellence Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab. NGC:008297. 2010. www.nice.org.uk\/nicemedia\/live\/13240\/51314\/51314.pdf (accessed 17 August 2012)"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0129|cit129","unstructured":"National Institute for Health and Clinical Excellence Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. 2010. www.nice.org.uk\/nicemedia\/live\/13045\/49855\/49855.pdf (accessed 17 August 2012)"},{"issue":"24","key":"10.1002\/14651858.CD008079.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008079.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0132|cit132","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V112.11.lba-1.lba-1","article-title":"Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory Chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial","volume":"112","author":"Robak","year":"2008","journal-title":"Blood"},{"issue":"27","key":"10.1002\/14651858.CD008079.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD008079.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.22662","article-title":"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia","volume":"109","author":"Shanafelt","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD008079.pub2-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008079.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008078","article-title":"Alemtuzumab for patients with chronic lymphocytic leukaemia","author":"Skoetz","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0139|cit139","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD008079.pub2-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004270","article-title":"Purine antagonists for chronic lymphocytic leukaemia","author":"Steurer","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008079.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunology Today"},{"issue":"6","key":"10.1002\/14651858.CD008079.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"18","key":"10.1002\/14651858.CD008079.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008079.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cncr.21554","article-title":"A retrospective comparison of three sequential groups of patients with Recurrent\/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens","volume":"106","author":"Wierda","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"10.1002\/14651858.CD008079.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008079.pub2-BIB0149|cit149","doi-asserted-by":"crossref","unstructured":"Wierda WG Padmanabhan S Chan GW Gupta IV Lisby S \u00d6sterborg A Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study Blood 2011 5126 9","DOI":"10.1182\/blood-2011-04-348656"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008079.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:02:46Z","timestamp":1761523366000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008079.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,14]]},"references-count":149,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008079.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,14]]}}}